Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC Thibaud P. Coroller, MSc, Vishesh Agrawal, MD, Elizabeth.

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer Yoshitaka Zenke, MD, Shigeki.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Erratum Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer Christina K. Speirs, MD, PhD, Todd.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI Jordyn Vernon, BHSc, Nicole Andruszkiewicz,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer Yoshitaka Zenke, MD, Shigeki.

Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model Lyudmila Bazhenova, MD, Paul Newton, PhD, Jeremy Mason, PhD, Kelly Bethel,

Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer Qurrat Mehmood, MBChB., Alexander.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,

Frank Detterbeck, MD Journal of Thoracic Oncology

Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective.

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer Pierre.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification.

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Tumor Response Kinetics after Schedule-Dependent Paclitaxel Chemoradiation Treatment for Inoperable Non-small Cell Lung Cancer: A Model for Low-Dose.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

M. Kusumoto Journal of Thoracic Oncology

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Presentation transcript:

Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC Thibaud P. Coroller, MSc, Vishesh Agrawal, MD, Elizabeth Huynh, PhD, Vivek Narayan, BSc, Stephanie W. Lee, BA, Raymond H. Mak, MD, Hugo J.W.L. Aerts, PhD Journal of Thoracic Oncology Volume 12, Issue 3, Pages 467-476 (March 2017) DOI: 10.1016/j.jtho.2016.11.2226 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A) Schematic of the radiomics quantification workflow demonstrating feature extraction from the lung primary tumor site (green) and lymph nodes (orange) from pretreatment computed tomography (CT) images. (B) Radiomics could enable precision medicine by classifying patients before therapy on the basis of how they will respond to chemoradiation. Journal of Thoracic Oncology 2017 12, 467-476DOI: (10.1016/j.jtho.2016.11.2226) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Areas under the curve of selected radiomic and conventional imaging features for pathological complete response versus non–pathological complete response (A) and gross residual disease versus non–gross residual disease (B). Selected features are derived from the primary tumor (PRIM) or lymph node(s) (LNs). The predictive power was reported as directly (Prop.) or inversely (Inv.) proportional to the risk for experiencing the event as the feature value is increased. Features reported with an asterisk are significant from a random guess (Noether’s test, p ≤ 0.05, false discovery rate–corrected). Legend colors indicate feature groups. WV, wavelet; glszm, Gray level size zone matrix; LoG, Laplacian of Gaussian; 3D, three-dimensional; MaxProb, maximum probability; GLCM, Gray level co-occurrence matrix; 2D, two-dimensional; Stats, statistics; H, High; L, Low; HLH, High-Low-High. Journal of Thoracic Oncology 2017 12, 467-476DOI: (10.1016/j.jtho.2016.11.2226) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 The performances of random forest classification of models for pathological complete response (A) and gross residual disease (B). Areas under the curve are reported from nested cross validation analysis. Asterisk indicates significant difference between the feature models (permutation test, p ≤ 0.05). ns, not significant; Clin., clinical; Rad., radiomics. Journal of Thoracic Oncology 2017 12, 467-476DOI: (10.1016/j.jtho.2016.11.2226) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions